Targeted Therapy for Severe Sjgren’s Syndrome: A Focus on Mesenchymal Stem Cells
Author Information
Author(s): Harrell Carl Randall, Volarevic Ana, Arsenijevic Aleksandar, Djonov Valentin, Volarevic Vladislav
Primary Institution: Regenerative Processing Plant, LLC
Hypothesis
The study investigates the therapeutic efficacy of mesenchymal stem cells (MSCs) in treating severe primary Sjögren’s syndrome (pSS).
Conclusion
Mesenchymal stem cells show promise in suppressing immune responses and promoting repair in patients with severe pSS.
Supporting Evidence
- MSCs can suppress the generation of inflammatory lymphocytes.
- MSCs promote the survival and repair of damaged salivary and lacrimal glands.
- Recent studies show MSCs have therapeutic efficacy in severe pSS.
Takeaway
This study looks at how special cells called mesenchymal stem cells can help people with a serious condition that makes their mouth and eyes dry.
Methodology
The review summarizes findings from various studies on the effects of MSCs in treating severe pSS.
Limitations
The findings are based on experimental studies and pilot clinical trials with small sample sizes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website